Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

Last updated: January 15, 2017
Sponsor: Xijing Hospital of Digestive Diseases
Overall Status: Completed

Phase

4

Condition

Heartburn (Pediatric)

Colic

Gastrointestinal Diseases And Disorders

Treatment

N/A

Clinical Study ID

NCT02633930
KY20151203-2
  • Ages 18-70
  • All Genders

Study Summary

This study aims at evaluating efficacy and safety of berberine-containing quadruple therapy(berberine, lansoprazole, bismuth and amoxicillin) versus clarithromycin-containing quadruple therapy (clarithromycin,lansoprazole, bismuth and amoxicillin) in H. pylori eradication. It is hypothesized that berberine-containing quadruple therapy is non-inferior to clarithromycin-containing quadruple therapy. Patients with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 2 and 6 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age between 18~70,both gender.

  2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.

  3. Patients are willing to receive eradication treatment.

  4. Women are eligible if they are not pregnant or nursing, and if they are ofchildbearing potential they are required to use medically acceptable contraception forthe duration of the study and 30 days thereafter.

Exclusion

Exclusion Criteria:

  1. Patients are excluded if they have previously used antibiotics to eradicate adequatelyrecorded infection with H. pylori.

  2. Contraindications to study drugs.

  3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.

  4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI)within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes (more than 3 times /1 month before screening)

  5. Pregnant or lactating women.

  6. Underwent upper gastrointestinal Surgery.

  7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom ofdysphagia.

  8. Evidence of bleeding or iron efficiency anemia.

  9. A history of malignancy.

  10. Drug or alcohol abuse history in the past 1 year.

  11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants, platelet aggregation inhibitors (except the use of aspirin for lessthan 100 mg/d).

  12. Enrolled in other clinical trials in the past 3 months.

Study Design

Total Participants: 566
Study Start date:
December 01, 2015
Estimated Completion Date:
August 31, 2016

Study Description

The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 28 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.

Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 12 and 14.

Follow-up: includes two visits. approximately 14 days of treatment and 28 days after the end of treatment. Eradication of H. Pylori will be confirmed through urea breath test(UBT).

Connect with a study center

  • Xijing Hospital of Digestive Disease

    Xi'an, Shanxi 710032
    China

    Site Not Available

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shanxi 710032
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.